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Abstract
Background
Although the involvement of intra-tumor genetic heterogeneity in tumor progression, treat-
ment resistance, and metastasis is established, genetic heterogeneity is seldom examined
in clinical trials or practice. Many studies of heterogeneity have had prespecified markers
for tumor subpopulations, limiting their generalizability, or have involved massive efforts
such as separate analysis of hundreds of individual cells, limiting their clinical use. We re-
cently developed a general measure of intra-tumor genetic heterogeneity based on whole-
exome sequencing (WES) of bulk tumor DNA, called mutant-allele tumor heterogeneity
(MATH). Here, we examine data collected as part of a large, multi-institutional study to vali-
date this measure and determine whether intra-tumor heterogeneity is itself related
to mortality.
Methods and Findings
Clinical and WES data were obtained from The Cancer Genome Atlas in October 2013 for
305 patients with head and neck squamous cell carcinoma (HNSCC), from 14 institutions.
Initial pathologic diagnoses were between 1992 and 2011 (median, 2008). Median time to
death for 131 deceased patients was 14 mo; median follow-up of living patients was 22 mo.
Tumor MATH values were calculated fromWES results. Despite the multiple head and
neck tumor subsites and the variety of treatments, we found in this retrospective analysis a
substantial relation of high MATH values to decreased overall survival (Cox proportional
hazards analysis: hazard ratio for high/low heterogeneity, 2.2; 95% CI 1.4 to 3.3). This rela-
tion of intra-tumor heterogeneity to survival was not due to intra-tumor heterogeneity’s asso-
ciations with other clinical or molecular characteristics, including age, human
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papillomavirus status, tumor grade and TP53mutation, and N classification. MATH im-
proved prognostication over that provided by traditional clinical and molecular characteris-
tics, maintained a significant relation to survival in multivariate analyses, and distinguished
outcomes among patients having oral-cavity or laryngeal cancers even when standard dis-
ease staging was taken into account. Prospective studies, however, will be required before
MATH can be used prognostically in clinical trials or practice. Such studies will need to ex-
amine homogeneously treated HNSCC at specific head and neck subsites, and determine
the influence of cancer therapy on MATH values. Analysis of MATH and outcome in human-
papillomavirus-positive oropharyngeal squamous cell carcinoma is particularly needed.
Conclusions
To our knowledge this study is the first to combine data from hundreds of patients, treated at
multiple institutions, to document a relation between intra-tumor heterogeneity and overall
survival in any type of cancer. We suggest applying the simply calculated MATH metric of
heterogeneity to prospective studies of HNSCC and other tumor types.
Introduction
High intra-tumor heterogeneity has long been hypothesized to lead to worse clinical outcome
[1–5]. Recent studies (reviewed in [6–11]) have documented the importance of intra-tumor
heterogeneity in tumor development, metastasis, and treatment resistance.
One particularly important type of intra-tumor heterogeneity arises from differences
among cancer cells that are inherited during cell division, which we refer to as genetic heteroge-
neity. Differences of a cancer cell’s genome from the germ line can result from unrepaired
copy-number aberrations (CNAs) (amplification or loss of chromosomes, chromosome arms,
or large genome segments) or smaller somatic mutations (single-nucleotide variants or short
genomic insertions or deletions) that are passed on to a cell’s lineage during tumor develop-
ment [12]. Even in a tumor originating from a single initiating clone, these processes can make
the genome diverge among the tumor’s cancer cells, leading to cells with different CNA pat-
terns [13] or to genetically distinct subclones [14]. This reservoir of genetically diverse cancer
cells can promote metastasis or allow resistance to cytotoxic or molecularly targeted therapies
[6–11].
Both CNAs and somatic mutations have been used to assess intra-tumor genetic heteroge-
neity and its relation to tumor development and patient outcomes. Gross CNAs seen via DNA
staining in flow cytometry [15] or in fixed tissue [16] have long been associated with poor out-
come. Intra-tumor differences in genome-segment amplification visualized by fluorescent in
situ hybridization have been used to map the progression of breast cancers [17] and to suggest
a mechanism for resistance to therapies targeted against individual receptor tyrosine kinases
[18]. Analyses of CNA patterns or somatic mutations in different portions of the same tumor,
even down to individual cells, have documented the importance of intra-tumor heterogeneity
in tumor biology [19–22] and have supported the early hypothesis [1] that preexisting resistant
subclones may be selected by therapy, leading to treatment failure [13].
The probable relation of intra-tumor genetic heterogeneity—whether from increased devia-
tion from the germ line in cells with CNAs or from an increasing number of subclones—to
poor outcome suggests that a measure of this heterogeneity would be a useful addition to
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cancer staging based on tumor node metastasis (TNM) [23] for prognosis. For patient care, im-
proving prognostic accuracy would aid the development of clinical trials that stratify cancer pa-
tients according to likely outcomes under standard-of-care therapy; furthermore, patients
whose tumors have low heterogeneity might be the best candidates for trials of targeted thera-
pies or treatment de-intensification. Measurement of intra-tumor heterogeneity might thus
eventually become an aid to clinical decision-making.
Incorporating information about intra-tumor genetic heterogeneity into clinical trial design
and decision-making would best be done with a simple, quantitative, generally applicable mea-
sure. There have, however, been no large-scale studies on the relation of such a measure of
intra-tumor heterogeneity to outcome for any type of cancer. Unfortunately, methods typically
used in research on intra-tumor heterogeneity (reviewed in [24]) would be difficult to use wide-
ly in clinical research or practice. Pre-identified markers of tumor subpopulations [17,18] may
not apply to tumor types other than those for which they were developed. Methods based on
general CNA analysis are more widely applicable, but without multiple sampling of a tumor (as
in [13]), they provide little information on intra-tumor heterogeneity caused by the presence of
multiple subclones. Multiple sampling of individual tumors [13,22] or single-cell analysis
[20,25] would be difficult to scale up for studies of hundreds of tumors or to assess in a timely
fashion prior to beginning treatment. Methods that combine information on somatic muta-
tions and copy-number changes to infer the subclonal composition of tumors [26–28] are still
highly specialized, are computationally intensive, and typically require an underlying theoreti-
cal model or tumor-type-specific empiric examples of intra-tumor subclonal relations [29].
To overcome these difficulties, we recently developed a simple measure of intra-tumor genetic
heterogeneity [30,31] based on whole-exome sequencing (WES) of tumor and matched normal
DNA.WithWES expected to play a significant role soon in clinical oncology [8,32], a measure
of heterogeneity based on this technology could be widely used in practice. For each genomic
locus having a tumor-specific mutation, WES provides the fraction of total sequenced DNA that
shows the mutant allele, the mutant-allele fraction (MAF). We noted that the MAF value at any
genomic locus would be influenced both by the presence of subclonal mutations and by CNAs.
Typically, a locus mutated early in the clonal evolution of a tumor will be shared among later-
arising subclones and have a highMAF in a bulk tumor specimen, while loci mutated later, re-
stricted to one or a few subclones, have lower MAFs. Also, a mutation present on a DNA seg-
ment that has undergone allele-specific genomic amplification or loss should have a higher or a
lower MAF, respectively, than a mutation at a locus that remains diploid. Because both subclonal
mutations and CNAs would be expected to lead to differences in MAF values among genomic
loci, we reasoned that the width of the distribution of MAF values among tumor-specific mutated
loci within an individual tumor might capture intra-tumor genetic heterogeneity arising from
both mechanisms. We thus proposed mutant-allele tumor heterogeneity (MATH), the width of
this distribution (normalized by the median MAF value to correct for normal DNA in the tumor
sample), as a simple quantitative measure of intra-tumor genetic heterogeneity [30].
In data from a prior study of patients with head and neck squamous cell carcinoma
(HNSCC) [33], higher intra-tumor heterogeneity as measured by MATH fromWES was relat-
ed to worse outcome, particularly in patients who had received chemoradiotherapy [31]. Gen-
eralizability of this result, however, was limited, as all 74 patients came from a single
institution. Furthermore, although human papillomavirus (HPV)–related HNSCC is of partic-
ular clinical interest because of its increasing incidence and improved clinical outcomes
[34–36], only 11 cases in that dataset were HPV-positive. Consequently, although HPV-
positive HNSCC tumors had significantly lower MATH values than HPV-negative tumors
[30], we were limited in our ability to establish separate relations of MATH and HPV status to
outcome because of the small sample size.
Intra-tumor Heterogeneity and Mortality
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To examine whether this relation between intra-tumor heterogeneity and mortality could
be generalized, we analyzed data on HNSCC from The Cancer Genome Atlas (TCGA) [37].
These open-access clinical and WES data provided an independent, large, multi-institutional
validation dataset for testing the relation of MATH to clinical outcome. We examined the rela-
tion of MATH values to standard clinical variables, including HPV status, and to three molecu-
lar characteristics of HNSCC: mutation rate, TP53mutations [38], and oncogenic signature
[12]. Using the same methods as in our previous work, we tested the hypothesis that intra-
tumor heterogeneity, as measured by MATH, was related to mortality in patients with HNSCC
after accounting for these potentially associated clinical and molecular characteristics.
Methods
The de-identified, publicly available clinical data used in this study were those released by
TCGA through October 8, 2013 [39]. The data tables downloaded on that date, for 360 pa-
tients, are provided as S1 Data. Initial pathologic diagnoses were between 1992 and 2011 (me-
dian, 2008). The TCGA head and neck consortium reported that the cases in the dataset were
generally representative of a surgical case series of primary HNSCC, with T1 tumors underrep-
resented because of the tissue sample sizes needed for the multiple types of analyses performed
on each tumor, and with most samples from the oral cavity or larynx [40,41]. Analysis of the
data from the multiple contributing TCGA institutions and comparison against nationwide
data support this characterization of the dataset (S1 Text).
For clinical data analysis, follow-up times and vital status reported in the main patient data
table were updated from the follow-up tables. TNM classification was based on pathologic de-
termination where available. Disease staging was as reported by TCGA. Radiation or chemo-
therapy delivered as primary therapy or adjuvant to surgery was distinguished from such
therapy for recurrent disease or for palliation based on the “radiation_therapy,” “postoperati-
ve_rx_tx,” “targeted_molecular_therapy,” “regimen_indication,” and “regimen_indication_
notes” fields in the TCGA patient, drug, radiation, and follow-up data tables. Absent a noted
indication, radiation or chemotherapy was deemed primary/adjuvant if delivered within 180 d
following initial pathologic diagnosis. As the University of Pittsburgh was the source of samples
in our previous study [30,31], we verified that there was no overlap between the Pittsburgh
cases we had already analyzed and the Pittsburgh TCGA cases.
Tumor-specific mutation data fromWES were downloaded from the Broad Institute of
MIT and Harvard [42], where WES had been performed [41]. Mutation data were available for
306 of the 360 patients with clinical data. To test and validate the results of our previous work
[30,31] directly, we used identical methods for MATH analysis. The steps in determining the
MATH value of an individual tumor from the WES data were (1) identifying genomic loci hav-
ing tumor-specific somatic mutations, based on tumor–normal DNA comparisons; (2) tabulat-
ing the MAF (the fraction of DNA that shows the mutated allele at a locus) for mutated loci in
that tumor; (3) determining the center and the width of the distribution of MAFs among those
loci; and (4) taking the ratio of the width to the center of the distribution, expressed as
a percentage.
Identification of tumor-specific mutations had already been performed at the Broad Insti-
tute of MIT and Harvard for TCGA, with the exome of tumor and matched normal DNA se-
lected by Agilent SureSelect methods, followed by Illumina HiSeq sequencing. Mean sequence
coverage was 95×, with 82% of bases in the targeted exome above 30× coverage [41]. The analy-
sis pipeline was as in a previous study [33], with tumor-specific mutations for each case deter-
mined by the MuTect algorithm [43]. For each tumor, this algorithm uses the numbers of
mutant and reference reads and the quality of the reads, in both tumor and patient-matched
Intra-tumor Heterogeneity and Mortality
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normal DNA, to estimate the likelihood that a particular locus has a tumor-specific rather than
a germ-line mutation. Loci that pass the assigned threshold likelihood are deemed to have
tumor-specific mutations. In total, 98.6% of mutant loci identified by MuTect in HNSCC and
tested independently were validated [41].
The publicly available compilation of HNSCC mutant-allele data contained the numbers of
WES reads showing the mutant allele and the number showing the reference allele at each
tumor-specific mutated genomic locus for each tumor. We calculated the MAF for each locus
as the ratio of mutant reads to total reads, and tabulated all MAF values for each tumor. For
comparison with our earlier work [30,31], based on WES data with no reported MAF below
0.075 [33], we restricted analysis to genomic loci having MAFs at or above that value; no fur-
ther restrictions were placed on the loci used for analysis. In one tumor, all mutations had
MAF values below that cutoff, so 305 cases remained for this study.
For each tumor we then determined the median and the median absolute deviation (MAD)
of its MAF values. The median is a robust measure of the center of the distribution of MAFs.
The MAD is a robust measure of the width of the distribution that is much less sensitive to out-
liers than the standard deviation (SD), and is determined as follows: the absolute value of the
difference of each MAF from the median MAF value is calculated, and the median of those ab-
solute differences is taken. This median difference is then multiplied by a factor of 1.4826, so
that the expected MAD of a normally distributed variable is equal to its SD.
Finally, the MATH value for each tumor was calculated as the percentage ratio of the MAD
to the median of the distribution of MAFs among the tumor’s mutated genomic loci [30]:
MATH = 100 ×MAD/median. Simply using the width of the distribution as a measure of geno-
mic heterogeneity would not take into account the overall lowering of MAF values by the “im-
purity” of normal DNA in the tumor sample. As previously described [30], dividing the MAD
by the median provides a first-order correction for this “impurity,” as a more “impure” sample
is expected to have a lower median MAF value.
Examples of the distributions of intra-tumor MAF values and how these translate to the tu-
mor’s MATH are shown for two cases in Fig. 1. In analyses that distinguished high- from low-
heterogeneity tumors, we used the same cutoff value of 32 MATH units as in the previous
study [31], without attempting to optimize the cutoff to the present data.
HPV status was based on the TCGAmolecular classification, with tumor samples having
more than 1,000 reads from RNA sequencing aligned to HPV sequences, or with evidence of
genomically integrated HPV DNA, deemed HPV-positive [41]. A tumor was judged to have
mutant TP53 if it had any non-silent mutation in that gene. M-class and C-class oncogenic sig-
natures were as reported by Ciriello et al. [12] for 267 of these tumors.
Relations of MATH values to other clinical and molecular characteristics were examined by
linear models. Relations of MATH values and these characteristics to overall survival (time be-
tween initial pathologic diagnosis and death) were assessed by Cox proportional
hazards analysis.
Receiver operating characteristic (ROC) curves for survival data were obtained by the near-
est neighbor method of Heagerty et al. [44]. This method provides a smoothed estimate of the
joint distribution of survival up to a chosen time and a continuous predictor variable. The
ROC curve based on that distribution represents the tradeoff between specificity and sensitivi-
ty, in terms of survival predictions at the chosen time, as the value of the predictor variable
(MATH in this case) is changed. Smoothing, by combining Kaplan-Meier survival analyses
from cases that are neighbors in terms of the predictor variable, allows use of censored survival
data, ensures a monotone relation between specificity and sensitivity, and makes ROC curves
independent of monotone transformations of the predictor variable. We used a smoothing
span of 0.1 (smoothing neighborhoods encompassing 10% of cases, except at the extremes of
Intra-tumor Heterogeneity and Mortality
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MATH values). Confidence intervals for the area under the curve (AUC) for ROC curves were
estimated from bootstrap samples.
Calculations were performed in the R software environment [45], including its survival,
boot, rms, and survivalROC packages. Significance analysis of hazard ratios (HRs) used the
Wald test. Statistical significance was accepted at p< 0.05 in two-sided tests.
Results
Clinical Characteristics and Their Relations to Outcome
Among the 305 TCGA HNSCC patients with both clinical data and tumor MATH values, age
ranged from 19 to 90 y, with a mean of 61.25, median of 61, SD of 12, and inter-quartile range
of 16. Initial pathologic diagnoses were made between 1992 and 2011 (median, 2008). The me-
dian follow-up time for 174 patients still living at last record was 22.5 mo (overall range, 0 to
142 mo; inter-quartile range, 24.5 mo), and the median time to death for the other 131 patients
was 14.3 mo (overall range, 0 to 211 mo; inter-quartile range, 16.4 mo). Thirty-six (12%) of the
patients’ tumors were HPV-positive by TCGAmolecular criteria.
Univariate relations of clinical characteristics to overall survival are shown in Table 1. In-
creased age, a history of smoking, higher T and N classifications, tumor grade, positive tumor
margins, and presence of perineural invasion or of extracapsular spread from lymph nodes
were all associated with diminished overall survival, and as expected [34,36,46,47], survival was
much better for patients with HPV-positive versus HPV-negative tumors, with an overall sur-
vival HR of 0.34.
Fig 1. Examples of distributions of intra-tumor MAFs and their relation to MATH values.Density plots
(smoothed histograms) of the distributions of MAFs for two HNSCCs. The horizontal-axis position of each
circle represents the MAF for a tumor-specific mutated locus in the indicated tumor sample, for loci having
MAFs no lower than 0.075: left, 117 loci; right, 106 loci. For each tumor, the median and the MAD of its MAFs
are indicated; each tumor MATH value is the percentage ratio of its MAD to its median. The vertical density
axis is scaled so that the area under the smoothed curve equals 1; a high peak density value indicates a
sharp peak. MAFs of mutated loci in the high-heterogeneity tumor (right panel) show a lower median and
higher MAD than those in the low-heterogeneity tumor (left panel), even though the total numbers of mutated
loci, a measure of mutation rates within the tumors, are similar.
doi:10.1371/journal.pmed.1001786.g001
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Table 1. Clinical and molecular characteristics, and their relations to overall survival.
Category Characteristic Number Percent Relation to Overall Survival
HR 95% CI p-Value#
Clinical characteristics Age 1.02/y 1.01–1.04 0.011
<56 y 93 30.5
56 to 65 y 102 33.4
>65 y 110 36.1
Gender
Female 84 27.5 1
Male 221 72.5 0.8 0.55–1.15 0.22
Race
White 264 86.6 1
American Indian/Alaska Native 1 0.3 No deaths
Asian 5 1.6 0.49 0.07–3.51 0.48
Black/African American 28 9.2 1.6 0.94–2.70 0.08
NA 7 2.3
Ethnicity
Hispanic/Latino 14 4.6 1
Not Hispanic/Latino 281 92.1 0.85 0.39–1.83 0.68
NA 10 3.3
Alcohol use (drinks per day)
<1 24 7.9 1
1 to 3 53 17.4 1.65 0.73–3.74 0.23
>3 43 14.1 1.65 0.69–3.98 0.26
NA 185 60.7
Tobacco history
Never smoked/quit >15 y 109 35.7 0.48 0.32–0.71 <0.001
Current smoker/quit 15 y 186 61.0 1
NA 10 3.3
Prior cancer diagnosis
No 288 94.4 1
Yes 17 5.6 0.86 0.38–1.97 0.73
Neoadjuvant history
No 296 97.0 1
Yes 9 3.0 1.44 0.69–2.99 0.33
Tumor site
Oral† 185 60.7 1.8 0.94–3.48 0.078
Oropharynx† 39 12.8 1
Larynx 78 25.6 1.7 0.84–3.45 0.14
Hypopharynx 3 1.0 1.88 0.24–14.7 0.55
T classiﬁcation* 1.22/class 1.02–1.46 0.031
1 24 7.9 1
2 92 30.2 1.55 0.60–3.98 0.36
3 81 26.6 2.67 1.05–6.77 0.039
4 108 35.4 2.21 0.88–5.55 0.091
Tumor histologic grade
G1 25 8.2 1
G2 187 61.3 2.17 1.08–4.37 0.03
(Continued)
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Table 1. (Continued)
Category Characteristic Number Percent Relation to Overall Survival
HR 95% CI p-Value#
G3 79 25.9 1.48 0.71–3.12 0.30
G4 4 1.3 No deaths
GX/NA 10 3.3
Tumor margins
Negative 213 69.8 1
Close 20 6.6 1.41 0.71–2.81 0.33
Positive 27 8.9 1.72 1.02–2.90 0.042
NA 45 14.8
Perineural invasion
Absent 101 33.1 1
Present 106 34.8 1.78 1.14–2.76 0.011
NA 98 32.1
Lymphovascular invasion
Absent 133 43.6 1
Present 65 21.3 1.4 0.89–2.20 0.14
NA 107 35.1
N classiﬁcation* 1.20/class 1.00–1.44 0.045
0 130 42.6 1
1 40 13.1 0.88 0.50–1.58 0.68
2 126 41.3 1.33 0.91–1.94 0.14
3 8 2.6 2.67 1.14–6.24 0.024
NA 1 0.3
TNM stage* 1.20/stage 0.99–1.46 0.067
I 17 5.6 1
II 53 17.4 2.12 0.63–7.06 0.22
III 48 15.7 2.4 0.72–8.05 0.15
IV 187 61.3 2.71 0.86–8.59 0.09
Extracapsular spread
None 136 44.6 1
Microscopic 37 12.1 2.36 1.42–3.92 0.001
Gross 18 5.9 1.75 0.91–3.38 0.096
NA 114 37.4
HPV status
Negative 242 79.3 0.34 0.16–0.70 0.003
Positive 36 11.8 1
NA 27 8.9
Tumor molecular characteristics Number of exome mutations 1.44/10-fold 0.90–2.30 0.13
<90 101 33.1
90 to 150 107 35.1
>150 97 31.8
TP53 status
Wild-type 92 30.2 1
Mutant 213 69.8 2.61 1.67–4.07 <0.001
Oncogenic signature
C-class 193 63.3 1
(Continued)
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HPV-positive HNSCC is now considered to be a different type of disease from HPV-
negative HNSCC [36]. As shown in S1 Table, HPV status was significantly related to many
clinical characteristics. Adjusting for HPV status did not affect the statistical significance of
most relations between clinical characteristics and overall survival (S2 Table). Exceptions were
T classification (no longer significant) and TNM stage (reached significance when analyzed as
a numeric variable adjusted for HPV status; S2 Table). These relations between clinical vari-
ables and outcome are expected in HNSCC [46], and support the clinical relevance of these
TCGA data.
We examined whether there were differences among the institutions that contributed tissue
samples and patient data to TCGA. As demonstrated in S1 Text, most of the apparent differ-
ences in survival among institutions could be attributed to different mixes of patient character-
istics among institutions, particularly in terms of HPV status.
MATH Values and Their Relation to Clinical Characteristics
Tumor MATH values ranged from 12.0 to 77.3, with a median of 37.0, a mean of 38.4, and first
and third quartiles of 29.0 and 46.4, respectively. The distribution of MATH values among tu-
mors is shown in Fig. 2.
Relations between MATH values and clinical characteristics were assessed by univariate lin-
ear models in which MATH value was the outcome variable and each clinical characteristic
was taken individually as a predictor variable. MATH value was significantly related to tumor
site, tumor grade, presence of lymphovascular invasion (LVI), and a history of prior cancer di-
agnosis or neoadjuvant therapy (Table 2). It was also highly related to tumor HPV status, vali-
dating our prior report [30]. The relations of selected patient clinical characteristics and tumor
molecular characteristics to MATH values are displayed in Fig. 3.
Given the importance of HPV in HNSCC, we examined whether adjusting for HPV status,
by including it as a second predictor variable in each of the linear models, would affect any of
the apparent relations between MATH values and clinical characteristics (Table 3). After this
adjustment for HPV, the relation between MATH value and anatomic tumor site was no longer
significant; the predominance of HPV-positive tumors in the oropharynx (S1 Table) apparent-
ly accounted for the low MATH values seen for oropharyngeal tumors in Table 2. This adjust-
ment for HPV exposed relations between MATH value and age and N classification, while
other clinical characteristics associated with MATH value in univariate analyses (Table 2)
maintained significance. MATH value was not significantly related to T classification or to
TNM stage, even after adjustment for HPV status.
We also examined whether tumor MATH values might provide information about the like-
lihood of regional metastases to lymph nodes. Among 194 patients with HPV-negative tumors
Table 1. (Continued)
Category Characteristic Number Percent Relation to Overall Survival
HR 95% CI p-Value#
M-class 96 31.5 0.62 0.42–0.92 0.018
NA 16 5.2
#p-Values for Wald test in univariate Cox proportional hazards analysis, omitting NA cases.
†Oral also includes oral tongue, lip, alveolar ridge, buccal mucosa, ﬂoor of mouth, and hard palate; oropharynx also includes base of tongue and tonsil.
*Results shown both for relation to outcome as numeric variable, and for individual categories.
NA, not available.
doi:10.1371/journal.pmed.1001786.t001
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whose cervical lymph nodes were examined pathologically, those with low-heterogeneity tu-
mors were significantly less likely to have disease that had spread to lymph nodes. Of the 64 pa-
tients with low-heterogeneity tumors, 42% (27) had positive nodes, versus 67% (87) of the 130
patients with high-heterogeneity (high MATH value) tumors (odds ratio, 2.76; 95% CI, 1.43 to
5.38; p = 0.001, Fisher exact test).
High Intra-Tumor Heterogeneity Was Related to Increased Mortality
MATH, taken as a continuous variable, was strongly related to overall survival; each 10% in-
crease in MATH value corresponded to an 8.8% increased hazard of death (95% CI, 3.3% to
15% increased hazard per 10% increase in MATH; p = 0.001). For comparison with the initial
study of MATH and survival in HNSCC [31], we used the previous MATH-value cutoff of 32
to distinguish high- from low-heterogeneity tumors; 194 tumors (63.6%) were thus classified as
high heterogeneity. Patients with high- versus low-heterogeneity tumors had double the hazard
of death (HR, 2.18; 95% CI, 1.44 to 3.30; p< 0.001; Fig. 4, left). The tradeoff between specificity
and sensitivity for 3-y survival predictions as the high/low MATH-value cutoff varied is illus-
trated in the ROC curve of Fig. 5 (left). A relation of intra-tumor heterogeneity to outcome has
long been suspected, particularly in patients treated with systemic therapy [1,3–5], and che-
moradiation is frequently used to treat advanced primary HNSCC [46]. We thus examined the
relation between MATH value and survival specifically in patients identified as receiving che-
moradiation as primary therapy or as an adjuvant to surgery. The relation of intra-tumor het-
erogeneity to outcome was also seen in this subset of 78 patients (HR, 5.2; 95% CI, 1.2 to 23;
p = 0.03; Fig. 4, right; ROC curve, Fig. 5, right), validating our prior results [30].
The Relation of MATH to Mortality Was Not Due to Its Relation to HPV or
to Other Clinical Characteristics
The relation of MATH values to clinical characteristics that are themselves associated with sur-
vival raised the question of whether the relation of MATH value to outcome simply
Fig 2. Histogram of MATH values among 305 HNSCCs.Horizontal axis, MATH values; vertical axis,
number of tumors having MATH values within the indicated ranges.
doi:10.1371/journal.pmed.1001786.g002
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Table 2. Relations of clinical and molecular characteristics to MATH values.
Category Characteristic Number Percent Relation to MATH Value
MATH ± SD# p-Value†
Clinical characteristics Age* −0.075/y ± 0.057 0.19
<56 y 93 30.5 39.4 ± 12.5
56 to 65 y 102 33.4 37.8 ± 12.3
>65 y 110 36.1 38.0 ± 10.9
Gender 0.27
Female 84 27.5 37.1 ± 9.9
Male 221 72.5 38.8 ± 12.5
Race 0.13
White 264 86.6 37.8 ± 11.7
American Indian/Alaska Native 1 0.3 49.4
Asian 5 1.6 35.3 ± 12.0
Black/African American 28 9.2 42.8 ± 12.4
NA 7 2.3 40.0 ± 13.8
Ethnicity 0.32
Hispanic/Latino 14 4.6 41.3 ± 11.9
Not Hispanic/Latino 281 92.1 38.0 ± 12.0
NA 10 3.3 43.1 ± 8.7
Alcohol use (drinks per day) 0.75
<1 24 7.9 37.8 ± 12.4
1 to 3 53 17.4 37.2 ± 11.3
>3 43 14.1 39.2 ± 13.8
NA 185 60.7 38.5 ± 11.6
Tobacco history 0.25
Never smoked/quit >15 y 109 35.7 37.2 ± 11.6
Current smoker/quit 15 y 186 61.0 38.9 ± 12.2
NA 10 3.3 40.1 ± 8.3
Prior cancer diagnosis 0.009
No 288 94.4 37.9 ± 11.7
Yes 17 5.6 45.6 ± 13.6
Neoadjuvant history 0.002
No 296 97.0 38.0 ± 11.5
Yes 9 3.0 50.6 ± 16.6
Tumor site 0.040
Oral‡ 185 60.7 37.9 ± 10.8
Oropharynx‡ 39 12.8 34.9 ± 14.3
Larynx 78 25.6 41.2 ± 12.7
Hypopharynx 3 1.0 34.8 ± 11.8
T classiﬁcation* +1.33/class ± 0.69 0.055
1 24 7.9 35.9 ± 11.8
2 92 30.2 36.6 ± 11.1
3 81 26.6 39.6 ± 12.0
4 108 35.4 39.3 ± 12.3
Tumor histologic grade 0.001
G1 25 8.2 33.4 ± 10.9
G2 187 61.3 39.7 ± 11.8
(Continued)
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Table 2. (Continued)
Category Characteristic Number Percent Relation to MATH Value
MATH ± SD# p-Value†
G3 79 25.9 37.9 ± 10.9
G4 4 1.3 20.8 ± 11.1
GX/NA 10 3.3 36.7 ± 16.1
Tumor margins 0.90
Negative 213 69.8 38.7 ± 10.6
Close 20 6.6 38.3 ± 11.9
Positive 27 8.9 39.7 ± 12.9
NA 45 14.8 35.7 ± 12.3
Perineural invasion 0.74
Absent 101 33.1 39.2 ± 12.3
Present 106 34.8 38.7 ± 10.6
NA 98 32.1 37.1 ± 12.8
LVI 0.005
Absent 133 43.6 37.5 ± 11.1
Present 65 21.3 42.4 ± 11.8
NA 107 35.1 36.9 ± 12.4
N classiﬁcation* +0.62/class ± 0.70 0.38
0 130 42.6 37.5 ± 12.4
1 40 13.1 39.2 ± 11.8
2 126 41.3 38.9 ± 11.4
3 8 2.6 38.1 ± 13.8
NA 1 0.3 50.0
TNM stage* +0.40/stage ± 0.72 0.58
I 17 5.6 38.5 ± 11.8
II 53 17.4 37.2 ± 11.8
III 48 15.7 38.5 ± 12.9
IV 187 61.3 38.6 ± 11.7
Extracapsular spread 0.11
None 136 44.6 37.3 ± 11.4
Microscopic 37 12.1 41.3 ± 10.2
Gross 18 5.9 40.9 ± 15.3
NA 114 37.4 38.2 ± 12.3
HPV status 0.004
Negative 242 79.3 39.8 ± 11.2
Positive 36 11.8 33.9 ± 13.5
NA 27 8.9 31.2 ± 12.2
Tumor molecular characteristics Number of exome mutations* +3.75/10-fold ± 1.83 0.041
<90 101 33.1 35.6 ± 12.7
90 to 150 107 35.1 40.5 ± 11.2
>150 97 31.8 38.8 ± 11.2
TP53 status <0.001
Wild-type 92 30.2 33.7 ± 12.2
Mutant 213 69.8 40.4 ± 11.2
Oncogenic signature <0.001
C-class 193 63.3 40.7 ± 11.2
(Continued)
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represented its relation to those other characteristics. We thus examined the joint relations of
MATH value and its associated characteristics to outcome, in bivariate and multivariate Cox
proportional hazards analyses.
Despite the strong association of HPV-positive tumors with low MATH values (Table 2),
both MATH value and HPV status were significantly related to overall survival in bivariate
Cox proportional hazards analysis. Fig. 6 (left) shows survival curves for combinations of high/
low MATH values and HPV status. This joint relation of MATH value and HPV status to out-
come supports a role of intra-tumor heterogeneity in HNSCC mortality independent of HPV
status [31].
Table 2. (Continued)
Category Characteristic Number Percent Relation to MATH Value
MATH ± SD# p-Value†
M-class 96 31.5 34.9 ± 12.3
NA 16 5.2 30.3 ± 8.6
#For variables analyzed as numeric, the value shown is the regression coefﬁcient for the change in MATH per change in the variable, ± the standard error
of the coefﬁcient.
†p-Values for linear analyses with MATH as outcome variable, omitting cases where data was not available for that characteristic.
*p-Values for analysis as numeric variables; MATH values by groups also shown.
‡Oral also includes oral tongue, lip, alveolar ridge, buccal mucosa, ﬂoor of mouth, and hard palate; oropharynx also includes base of tongue and tonsil.
NA, not available.
doi:10.1371/journal.pmed.1001786.t002
Fig 3. Relations of selected clinical andmolecular characteristics to MATH values. Each panel
represents the relation of a clinical or molecular characteristic to MATH values. Within each panel, the
horizontal axis represents the range of tumor MATH values, divided into five groups with approximately equal
numbers of tumors. The relative heights of the shaded portions within each vertical bar indicate the
proportions of cases having the indicated characteristics.
doi:10.1371/journal.pmed.1001786.g003
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We then examined whether other clinical characteristics that were associated both with
MATH values and with overall survival might account for the relation of MATH to survival.
After adjustment for HPV status, only the clinical characteristics of age, tumor grade, and N
classification were significantly associated with both MATH values (Table 3) and overall sur-
vival (S2 Table). To evaluate whether these correlated clinical characteristics might account for
the relation of MATH to outcome, we performed multivariate survival analysis incorporating
these three clinical characteristics, HPV status, and MATH value. MATH value remained sig-
nificantly related to overall survival in this analysis (S3 Table). Thus, MATH value is associated
with survival after adjustment for correlated clinical characteristics.
Table 3. Relations of clinical and molecular characteristics to MATH values, adjusting for HPV status.
Category Characteristic MATH Value ± SD (Number of Cases) p-Value#
HPV-Negative HPV-Positive
Clinical characteristics Age† 0.046
<56 y 41.4 ± 10.2 (68) 35.0 ± 15.4 (15)
56 to 65 y 40.2 ± 12.3 (80) 30.0 ± 9.5 (12)
>65 y 38.4 ± 10.8 (94) 37.2 ± 14.8 (9)
Prior cancer diagnosis 0.042
No 39.8 ± 11.3 (232) 31.5 ± 11.1 (32)
Yes 40.6 ± 7.7 (10) 52.9 ± 17.1 (4)
Neoadjuvant history 0.026
No 39.7 ± 11.1 (236) 32.8 ± 12.5 (34)
Yes 45.6 ± 12.9 (6) 52.0 ± 22.2 (2)
Tumor histologic grade 0.005
G1 33.4 ± 11.3 (22) 24.9 (1)
G2, G3, or G4 40.3 ± 10.9 (215) 34.7 ± 13.8 (32)
LVI 0.002
Absent 38.4 ± 10.8 (115) 32.4 ± 13.6 (11)
Present 44.2 ± 11.5 (57) 32.7 ± 5.1 (2)
N classiﬁcation† 0.039
0 38.0 ± 11.5 (107) 33.5 ± 15.6 (13)
1 39.7 ± 10.8 (34) 39.6 ± 17.3 (5)
2 41.5 ± 10.8 (95) 32.8 ± 11.3 (17)
3 44.5 ± 9.3 (5) 29.0 (1)
Molecular characteristics TP53 status
Wild-type 36.3 ± 12.4 (42) 33.0 ± 12.6 (35) 0.009
Mutant 40.6 ± 10.8 (200) 65.1 (1)
Oncogenic signature 0.001
C-class 41.5 ± 10.3 (170) 38.8 ± 14.1 (11)
M-class 36.7 ± 12.4 (65) 32.0 ± 13.4 (21)
Analysis restricted to the 278 tumors with data on HPV status. In bivariate linear analyses including HPV status, MATH values were not signiﬁcantly
related to gender (3.0 units higher in males, p = 0.055), the number of mutated loci (3.2 units higher per 10-fold increase in number of loci, p = 0.092), T
classiﬁcation (1.1 units higher per T class, p = 0.12), nodal extracapsular spread (3.6 units higher, p = 0.12, among pN+ nodes), or any of the following
(p > 0.15): ethnicity, race, tumor site, alcohol use, tobacco use, TNM stage, tumor margin status, or perineural invasion.
#For relation of MATH to indicated characteristic in bivariate linear analysis with HPV status.
†Analyzed as numeric; age groups for display.
doi:10.1371/journal.pmed.1001786.t003
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The Relation of MATH to Mortality Was Not Due to Its Relation to Other
Molecular Characteristics of the Tumors
In univariate analyses, MATH values were related to three other molecular characteristics of
the tumors: the number of somatic mutations in the exome (a measure of tumor mutation rate
[33]), TP53mutation status [38], and oncogenic signature class [12] (Table 2, bottom). We
Fig 4. Relation of intra-tumor heterogeneity to overall survival in HNSCC. Kaplan-Meier curves for patients with high- or low-heterogeneity tumors,
based on the MATH-value cutoff of 32 used in a previous study [31]. Left, for all 305 patients. Right, for 78 patients receiving chemoradiation as primary
therapy or as an adjuvant to surgery. Corresponding HRs, confidence intervals, and p-values are in the main text.
doi:10.1371/journal.pmed.1001786.g004
Fig 5. MATH receiver operating characteristic curves. Time-dependent ROC curves (solid lines) evaluated at 3-y survival, obtained by the nearest
neighbor method of Heagerty et al. [44], with a smoothing span of 0.1. Curves show the relation between sensitivity (true-positive fraction) and specificity (1 −
false-positive fraction) as the MATH value used to distinguish high- from low-heterogeneity tumors (values shown along the curves) is altered. Dashed lines
are lines of identity. Left, ROC curve for all 305 patients (95% CI for AUC, 0.60 to 0.74). Right, ROC curve for 78 patients receiving chemoradiation as primary
therapy or as an adjuvant to surgery (95%CI for AUC, 0.54 to 0.82).
doi:10.1371/journal.pmed.1001786.g005
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thus examined whether the relations of these molecular characteristics to MATHmight ac-
count for its relation to overall survival.
First, although a tumor’s mutation rate as measured by its number of exome mutations was
associated with MATH values in univariate analysis (Table 2), this relation was no longer sig-
nificant after adjustment for HPV status (Table 3), and mutation rate was not itself significant-
ly related to overall survival (Table 1), particularly after adjustment for HPV (S2 Table). These
results ruled out mutation rate as an explanation for the relation of MATH to outcome.
Second, MATH values were significantly higher in HPV-negative tumors that harbored
TP53mutations than in HPV-positive/TP53 wild-type tumors (Table 3), and as expected [38],
mutated TP53 was significantly related to diminished overall survival (HR, 2.61; 95% CI, 1.67
to 4.07; p< 0.001). As shown in Fig. 6 (right), however, both MATH and TP53mutation status
were significantly related to survival among patients with HPV-negative tumors. (Only one
HPV-positive tumor bore a mutation in TP53.) Thus, both high MATH value and mutated
TP53 were associated with survival after adjustment for their relation to each other.
Third, a novel molecular classification based on frequently occurring DNA disruptions
among multiple types of tumors, called the oncogenic signature [12], was related both to sur-
vival and to MATH value. Oncogenic signatures are genomic classifications based on over
3,000 TCGA tumors from multiple anatomic sites, with the major classes called “M” and “C.”
Disruptions in M-class tumors are dominated by small mutations (single nucleotide variants
and small indels), versus predominant CNAs in C-class tumors. Oncogenic signature class had
a significant univariate relation to outcome, with better overall survival in patients with M-
class tumors (Table 1). Furthermore, MATH value in M-class tumors was significantly lower
than in C-class tumors, even when HPV status was taken into account (Table 3), while HPV-
Fig 6. Combined relation of MATH and HPV or TP53mutation status to overall survival. Left, joint relation of intra-tumor heterogeneity and HPV status
to overall survival in HNSCC among 278 patients whose tumor HPV status had been assessed by TCGAmolecular criteria (see Methods). Kaplan-Meier
curves are for the indicated combinations of HPV and MATH status; high MATH is MATH> 32. Blue, low MATH value; red, high MATH value; dashed lines,
HPV-positive; solid lines, HPV-negative. Cox proportional hazards analysis: high/lowMATH HR, 1.85 (95%CI, 1.22 to 2.80; p = 0.004, Wald test); HPV-
positive/-negative HR, 0.36 (95%CI, 0.18 to 0.74; p = 0.006). Right, joint relation of intra-tumor heterogeneity and TP53mutation status to overall survival in
HNSCC among 242 patients with HPV-negative tumors. Kaplan-Meier curves are for the indicated combinations of TP53 and MATH status. Dashed lines,
wild-type (WT) TP53; solid lines, mutant TP53. Cox proportional hazards analysis: high/low MATHHR, 1.62 (95%CI, 1.04 to 2.52; p = 0.031, Wald test);
mutant/wild-type TP53HR, 1.75 (95%CI, 1.002 to 3.05; p = 0.049).
doi:10.1371/journal.pmed.1001786.g006
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positive tumors were predominantly in the M class (HPV-positive tumors: 11 C-class, 21 M-
class; HPV-negative tumors: 170 C-class, 65 M-class; p< 0.001, Fisher exact test). We exam-
ined the joint relation of oncogenic signature class, HPV status, and MATH value to outcome
in Cox proportional hazards analysis. In this trivariate analysis, oncogenic signature class was
no longer associated significantly with outcome (M-class/C-class HR, 0.88; 95% CI, 0.57 to
1.34; p = 0.54), while MATH value (high/low HR, 1.75; 95% CI, 1.11 to 2.72; p = 0.015) and
HPV status (HVP-positive/-negative HR, 0.31; 95% CI, 0.13 to 0.71; p = 0.006) both remained
significantly related to outcome. Thus, the relation of high MATH value to increased mortality
is not due to its associations with the tumor molecular characteristics of mutation rate, TP53
mutation, and oncogenic signature.
MATH Contributes Clinically Useful Prognostic Information
Having found that the relation of high MATH value to increased mortality was not simply due
to its relations to patient clinical characteristics or to other molecular characteristics of the tu-
mors, we examined whether MATH could further aid in prognostication.
We examined whether MATH could improve prognostication in oral-cavity or laryngeal tu-
mors. HPV and its associated better prognosis is seldom involved at these anatomic sites [36],
unlike oropharyngeal tumors, so that additional prognostic information beyond that provided
by TNM staging [23] is needed. High versus low MATH value significantly distinguished out-
comes in patients with tumors at either site (Fig. 7, top), even when TNM staging was taken
into account (Fig. 7, bottom). These results support MATH as an additional prognostic vari-
able for patients with tumors at those sites.
Another use of MATH could be in multivariate survival models that incorporate clinical
and molecular characteristics to stratify patients by expected outcome for clinical trials or clini-
cal decision-making. We thus examined MATH along with variables known to be associated
with HNSCC outcome—HPV and TP53 status, and seven standard clinical characteristics—in
multivariate Cox proportional hazards analysis, which adjusts for the relations among all the
predictors. In this multivariate analysis, MATH value, age, and smoking history were found to
be significantly related to outcome (Table 4).
Discussion
These results validate and substantially extend our previous finding [31] that high intra-tumor
heterogeneity predicts decreased overall survival in patients with HNSCC. Even after account-
ing for clinical and molecular characteristics of patients and their tumors, the magnitude of the
mortality hazard associated with high intra-tumor heterogeneity, as measured by MATH
(Table 4), was comparable to that of hazards associated with established prognostic variables
(Tables 1 and 4).
What the Study Adds to Existing Research
Intra-tumor heterogeneity and cancer mortality. To our knowledge, this is the first large-
scale demonstration based on data from multiple institutions that intra-tumor heterogeneity
per se is clinically important in the prognosis of any type of cancer. Using identical criteria for
including tumor-specific mutated loci, calculating MATH values, and distinguishing high-
from low-heterogeneity tumors as in the previous single-institution study, the present study
found a highly significant relation of high intra-tumor heterogeneity to outcome. In both stud-
ies, the univariate overall survival HR for high/low MATH was over 2 (previous study, 2.46;
this study, 2.18), and a relation of high intra-tumor heterogeneity to decreased overall survival
was seen among patients receiving chemoradiotherapy (HR in previous study, 4.1; this study,
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5.2). We found this strong relation of intra-tumor heterogeneity to overall survival despite the
limitations of these TCGA data. In particular, the data were not collected with this analysis of
heterogeneity in mind, and the variety of institutions, head and neck tumor subsites, and treat-
ment modalities might have been expected to minimize our ability to identify significant prog-
nostic variables. Our results thus suggest that intra-tumor heterogeneity can have substantial
clinical importance.
Fig 7. MATH value andmortality in patients with tumors in the oral cavity or the larynx. Left, patients with oral-cavity tumors; right, patients with
laryngeal tumors. Top, Kaplan-Meier curves for all patients. Blue, low MATH; red, high MATH (MATH> 32). Cox proportional hazards analysis: oral cavity,
high/lowMATH HR, 1.69 (95%CI, 1.04 to 2.73; p = 0.033); larynx, high/low MATHHR, 3.55 (95%CI, 1.25 to 10.1; p = 0.018). Bottom, joint relation of MATH
value and disease stage to survival; dashed, lines Stages I–III; solid lines, Stage IV. Cox proportional hazards analysis: oral cavity, high/lowMATH HR, 1.67
(95%CI, 1.03 to 2.70; p = 0.037, Wald test); Stage IV/Stage I–III HR, 1.34 (95%CI, 0.87 to 2.08; p = 0.19); larynx, high/lowMATH HR, 3.50 (95% CI, 1.18 to
10.4; p = 0.024); Stage IV/Stage I–III HR, 1.04 (95%CI, 0.44 to 2.49; p = 0.92).
doi:10.1371/journal.pmed.1001786.g007
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Sources and consequences of intra-tumor heterogeneity. The intra-tumor genetic hetero-
geneity captured by MATH may arise from either CNAs or from subclonal mutations. Al-
though the present results do not distinguish CNAs from subclonality, they do shed some light
on the consequences of high intra-tumor heterogeneity and the processes that promote it. High
MATH values in tumors containing TP53mutations suggest that deficiencies in DNA-damage
and apoptotic responses may create an environment that is favorable to the generation or
maintenance of intra-tumor genetic heterogeneity. High MATH values in tumors with the mo-
lecular C-class oncogenic signature [12], even after adjustment for HPV status, support a
stronger role of CNAs than of point mutations in developing or maintaining intra-tumor het-
erogeneity as measured by MATH. Nevertheless, heterogeneity per se, rather than CNAs,
seems most closely related to HNSCC outcome, as the low univariate M-class/C-class HR be-
came insignificant once MATH and HPV status were taken into account. The relation of high
MATH value to LVI and nodal status suggests that intra-tumor heterogeneity may foster re-
gional metastasis. The relation of high MATH value to decreased survival in patients receiving
cytotoxic therapy supports selection of preexisting resistant cancer cells by therapy [1,13] or
the presence in heterogeneous tumors of subpopulations that provide resistance or promote
the growth of the rest of the tumor [48] as mechanisms for evading such therapy. As these ini-
tial findings are expanded by further study on the mechanisms underlying the development of
intra-tumor heterogeneity, it might become possible to turn those mechanisms into
therapeutic targets.
Prognostic variables in HNSCC. These results highlight important issues to address in
HNSCC prognostic models. First, some clinical characteristics related to overall survival
(Table 1) are often difficult or impossible to evaluate in clinical practice in patients with low-T/
high-N disease, where a tumor biopsy is performed to help choose definitive therapy. If therapy
does not include surgical tumor excision or neck dissection [46], information on tumor mar-
gins, perineural invasion, LVI, and nodal extracapsular spread will be incomplete or unavail-
able. A MATH value, obtained fromWES of a few milligrams of a tumor, does not face this
Table 4. Multivariate relation of MATH value and standard prognostic variables to overall survival.
Clinical or Molecular Characteristic HR 95% CI p-Value
Low High
MATH > 32 1.76 1.13 2.74 0.013
Age (per year) 1.03 1.01 1.06 0.013
Non-smoker, or quit >15 y 0.52 0.30 0.89 0.018
N classiﬁcation > 1 1.69 0.93 3.07 0.083
HPV-positive 0.39 0.10 1.59 0.19
Tumor grade > 1 1.49 0.67 3.29 0.33
T classiﬁcation > 2 1.24 0.73 2.12 0.42
Stage IV 0.78 0.38 1.63 0.52
TP53 mutant 1.17 0.62 2.20 0.64
Male gender 0.89 0.51 1.56 0.69
Results of multivariate Cox proportional hazards analysis for 261 patients (114 deceased) with complete
information on the indicated variables. Conﬁdence intervals and p-values are based on a bootstrap
estimate (400 resamples) of the variance–covariance matrix. There was some evidence of non-proportional
hazards for tumor grade (p = 0.082, chi-square test for trend of residuals with time); a model stratiﬁed by
tumor grade gave similar results with no evidence of non-proportional hazards (p > 0.3 for all variables).
doi:10.1371/journal.pmed.1001786.t004
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limitation as a biomarker. Second, the close relations among TP53mutation status, HPV status,
MATH value, and clinical characteristics mean that care must be taken in interpreting and
using prognostic models in HNSCC. For example, the lack of statistical significance of N classi-
fication, HPV status, and TP53mutation in the ten-variable multivariate analysis shown in
Table 4 does not mean that they are irrelevant to outcome; each of these characteristics bears a
significant univariate relation to outcome in HNSCC (Table 1), and their apparent lack of sig-
nificance in the multivariate model might simply represent the difficulty in unraveling the indi-
vidual contributions of multiple highly correlated variables, particularly with only 36 HPV-
positive tumors.
Strengths and Limitations of This Study
Strengths. This study was designed as a validation test of the relation between mortality and
MATH that we had found in a previous smaller, single-institution study. We used the previous
methods for calculating MATH values, and the previous MATH cutoff between high- and low-
heterogeneity tumors, without any attempt to optimize for the present data. The large number
of patients and the multiple institutions represented in the TCGA data on HNSCC provided a
stringent test of our previous findings, and allowed us to adjust for many clinical and molecular
variables in our analyses of overall survival. Thus, the association of high intra-tumor heteroge-
neity in HNSCC with increased mortality has been validated insofar as possible with this type
of retrospective analysis.
Limitations. To define the usefulness of MATH in HNSCC and to extend similar analyses
to other types of cancer, further work is needed to overcome several limitations of the present
study. One issue is how MATH is measured in practice. In both this study and the previous re-
port [31], MATH values were determined fromWES data obtained with a consistent set of
methods, from tumor processing through exome capture (and thus breadth of genomic se-
quencing coverage) to WES (at similar depth of sequencing) and calling of somatic mutations.
As discussed previously [30], different combinations of technologies might lead to different or
less reliable MATH values, in particular if a lower breadth of coverage limits the number of
tumor-specific mutations found or if calling methods for somatic mutations or handling of loci
with low MAFs differs from the methods in the present study. Also, given that the precision of
determining a tumor’s MATH value depends on its number of tumor-specific mutated geno-
mic loci [30], exome capture for a type of cancer with lower mutation rates than HNSCC
might not provide enough tumor-specific mutations, so that a larger fraction of the genome
might need to be sequenced.
Another issue is that the simplicity of the formula for calculating MATH values fromWES
data masks important aspects of underlying tumor biology. The MAFs observed in a bulk
tumor DNA sample are determined by several factors: the “impurity” arising from normal
DNA in non-cancer cells, the cancer-cell genomic ploidy arising from large-scale gain or loss
of chromosomal segments or smaller-scale CNAs, and mutations specific to genetically distinct
subclones within the tumor. Several methods have been developed to untangle these contribu-
tions [26–29]. The MATHmeasure of heterogeneity uses the median MAF value of the tumor
as a first-order correction for “impurity,” and it combines heterogeneity arising from ploidy/
CNAs and subclones, as both can contribute to the width of the distribution of a tumor’s MAF
values [30]. More precise corrections for impurity and separate handling of ploidy and subclo-
nal tumor inheritance patterns might ultimately lead to better measures of intra-tumor hetero-
geneity, but for now MATH provides a simple measure, closely related to mortality in HNSCC,
that can be determined as soon as tumor-specific mutations have been called and MAF values
are available.
Intra-tumor Heterogeneity and Mortality
PLOSMedicine | DOI:10.1371/journal.pmed.1001786 February 10, 2015 20 / 27
Finally, several limitations of the TCGA clinical data need to be recognized. First, the TCGA
requirement for tumor mass adequate for multiple analyses biases this dataset toward larger,
surgically treated tumors and underrepresents the increasingly important HPV-positive
HNSCC that often presents with low-T/high-N pathology [40] (see S1 Text); of 305 tumors,
only 24 (three HPV-positive) were T1. Second, our use of statistical models to account for the
contribution of HPV status to other clinical variables and to outcome might not properly cap-
ture the different biological bases and clinical history of HPV-positive and HPV-negative
HNSCC. Coefficients in analyses that take HPV status into account in this way are necessarily
weighted toward the more prevalent HPV-negative cases, and there were too few HPV-positive
cases to allow analysis of the HPV-positive subset or of statistical interaction coefficients in-
volving HPV status. Third, although much information about clinical treatments and out-
comes was available from TCGA, these data were not collected prospectively, and many cases
lacked complete treatment annotations. Thus, we could not, for example, resolve the important
issue of whether high heterogeneity predicts shorter survival in patients treated solely with sur-
gery. Finally, although Table 4 clearly demonstrates that MATH has a prognostic significance
similar to that of accepted outcome markers in HNSCC, this particular multivariate model
should not be used for clinical prognostication. Prospective study of homogeneously treated
HNSCC at specific head and neck subsites, with appropriate model validation, will be required
before such results can be used in clinical trials or in routine clinical practice. Further analysis
of MATH and outcome specifically in HPV-positive oropharyngeal squamous cell carcinoma
is particularly needed.
Implications
The strong relation of higher intra-tumor heterogeneity as measured by MATH to decreased
overall survival means that MATH should be considered a biomarker in HNSCC. The limita-
tions of the present study, noted above, should be addressed by analyzing tumor specimens al-
ready collected in prospective clinical studies or by incorporating MATH analysis into future
studies. Once validated in this way, MATH values will be able to provide a simple high/low het-
erogeneity characterization (Figs. 4, 6, and 7) or a continuous measure of intra-tumor hetero-
geneity (Fig. 5) in models designed for prognostication or for clinical trial designs that require
identifying patients who are at either particularly high or low risk of succumbing to disease
under current standards of care. In particular, with its relation to outcome following chemora-
diation (Fig. 4, right) and its joint relation with HPV status to outcome (Fig. 6, left), MATH
should be useful in clinical trials on de-intensification of organ-preservation therapy for oro-
pharyngeal cancer, in which chemoradiation is a standard of care and HPV status is already
considered in trial design [36]. In HPV-negative HNSCC, the relation of MATH to nodal in-
volvement suggests that MATHmight assist clinical studies in evaluating the need for cervical
node dissection in patients with low-T/cN0 oral cancer, a decision presently based on tumor
depth and sentinel node mapping [49]. Furthermore, MATH adds usefully to TNM staging in
prognosticating overall survival of patients having either oral-cavity or laryngeal tumors
(Fig. 7). Consequently, MATH could direct the need for adjuvant therapy or identify candi-
dates for laryngeal preservation protocols. As HPV status has helped stratify patients with oro-
pharyngeal tumors according to prognosis [36,46], MATHmay help stratify patients with
tumors at these head and neck sites where HPV-positive tumors are infrequent.
More generally, MATH will be straightforward to apply clinically in other types of cancer,
for there is nothing specific to HNSCC in the underlying analysis of exome sequence data. Un-
like approaches to measuring intra-tumor heterogeneity that require pre-identification of sub-
clone markers [17,18], detailed analysis of SNP arrays [26,50], or analysis of multiple portions
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down to single cells of a tumor [13,20,22,25], MATH calculations require no information be-
yond a list of tumor-specific mutations and their MAFs, derived directly from a patient’s
tumor and normal DNA. Thus, as WES enters the practice of clinical oncology [8,32], MATH
will provide a novel and straightforward way to incorporate information about intra-tumor
heterogeneity into clinical research and practice.
Conclusions
Intra-tumor heterogeneity per se can be prognostically important in cancer. MATH, a novel
measure of intra-tumor genetic heterogeneity, has a prognostic relation to outcome compara-
ble to that of accepted biomarkers in HNSCC clinical oncology, adding information beyond
that provided by other patient and tumor characteristics. The success in relating MATH to out-
come in HNSCC supports its evaluation in other types of cancer.
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Editors’ Summary
Background
Normally, the cells in human tissues and organs only reproduce (a process called cell divi-
sion) when new cells are needed for growth or to repair damaged tissues. But sometimes a
cell somewhere in the body acquires a genetic change (mutation) that disrupts the control
of cell division and allows the cell to grow continuously. As the mutated cell grows and di-
vides, it accumulates additional mutations that allow it to grow even faster and eventually
from a lump, or tumor (cancer). Other mutations subsequently allow the tumor to spread
around the body (metastasize) and destroy healthy tissues. Tumors can arise anywhere in
the body—there are more than 200 different types of cancer—and about one in three peo-
ple will develop some form of cancer during their lifetime. Many cancers can now be suc-
cessfully treated, however, and people often survive for years after a diagnosis of cancer
before, eventually, dying from another disease.
WhyWas This Study Done?
The gradual acquisition of mutations by tumor cells leads to the formation of subpopula-
tions of cells, each carrying a different set of mutations. This “intra-tumor heterogeneity”
can produce tumor subclones that grow particularly quickly, that metastasize aggressively,
or that are resistant to cancer treatments. Consequently, researchers have hypothesized
that high intra-tumor heterogeneity leads to worse clinical outcomes and have suggested
that a simple measure of this heterogeneity would be a useful addition to the cancer staging
system currently used by clinicians for predicting the likely outcome (prognosis) of pa-
tients with cancer. Here, the researchers investigate whether a measure of intra-tumor het-
erogeneity called “mutant-allele tumor heterogeneity” (MATH) is related to mortality
(death) among patients with head and neck squamous cell carcinoma (HNSCC)—cancers
that begin in the cells that line the moist surfaces inside the head and neck, such as cancers
of the mouth and the larynx (voice box). MATH is based on whole-exome sequencing
(WES) of tumor and matched normal DNA. WES uses powerful DNA-sequencing systems
to determine the variations of all the coding regions (exons) of the known genes in the
human genome (genetic blueprint).
What Did the Researchers Do and Find?
The researchers obtained clinical and WES data for 305 patients who were treated in 14 in-
stitutions, primarily in the US, after diagnosis of HNSCC from The Cancer Genome Atlas,
a catalog established by the US National Institutes of Health to map the key genomic
changes in major types and subtypes of cancer. They calculated tumor MATH values for
the patients from their WES results and retrospectively analyzed whether there was an as-
sociation between the MATH values and patient survival. Despite the patients having tu-
mors at various subsites and being given different treatments, every 10% increase in
MATH value corresponded to an 8.8% increased risk (hazard) of death. Using a previously
defined MATH-value cutoff to distinguish high- from low-heterogeneity tumors, com-
pared to patients with low-heterogeneity tumors, patients with high-heterogeneity tumors
were more than twice as likely to die (a hazard ratio of 2.2). Other statistical analyses indi-
cated that MATH provided improved prognostic information compared to that provided
by established clinical and molecular characteristics and human papillomavirus (HPV)
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status (HPV-positive HNSCC at some subsites has a better prognosis than HPV-negative
HNSCC). In particular, MATH provided prognostic information beyond that provided by
standard disease staging among patients with mouth or laryngeal cancers.
What Do These Findings Mean?
By using data from more than 300 patients treated at multiple institutions, these findings
validate the use of MATH as a measure of intra-tumor heterogeneity in HNSCC. More-
over, they provide one of the first large-scale demonstrations that intra-tumor heterogene-
ity is clinically important in the prognosis of any type of cancer. Before the MATHmetric
can be used in clinical trials or in clinical practice as a prognostic tool, its ability to predict
outcomes needs to be tested in prospective studies that examine the relation between
MATH and the outcomes of patients with identically treated HNSCC at specific head and
neck subsites, that evaluate the use of MATH for prognostication in other tumor types,
and that determine the influence of cancer treatments on MATH values. Nevertheless,
these findings suggest that MATH should be considered as a biomarker for survival in
HNSCC and other tumor types, and raise the possibility that clinicians could use MATH
values to decide on the best treatment for individual patients and to choose patients for in-
clusion in clinical trials.
Additional Information
Please access these websites via the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001786.
• The US National Cancer Institute (NCI) provides information about cancer and how it
develops and about head and neck cancer (in English and Spanish)
• Cancer Research UK, a not-for-profit organization, provides general information about
cancer and how it develops, and detailed information about head and neck cancer; the
Merseyside Regional Head and Neck Cancer Centre provides patient stories about
HNSCC
• Wikipedia provides information about tumor heterogeneity, and about whole-exome
sequencing (note that Wikipedia is a free online encyclopedia that anyone can edit;
available in several languages)
• Information about The Cancer Genome Atlas is available
• A PLOS Blog entry by Jessica Wapner explains more about MATH
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